hackint0sh/New-Dataset huggingface dataset:
* to compare gut microbiome composition and patient-reported outcome measures between groups from baseline to six weeks post-surgery conditions: Total Knee Arthroplasty conditions: Inflammation conditions: Gastrointestinal Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Probiotic Formula Bacillus subtilis name: Placebo measure: Implant Migration measure: Bone Density measure: Magnitude of 18-F-Fluoroethyl(2-(2-fluoroethoxy)phenyl)-proprionate ([¹⁸F]FEPPA) Tracer Uptake measure: Veterans Rand 12-Item Health Survey (VR-12) measure: EuroQol-5D (EQ-5D) measure: Western Ontario McMaster Osteoarthritis Index (WOMAC) measure: Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) measure: Patient Global Assessment (PGA) measure: University of California, Los Angeles (UCLA) Activity Score measure: Oxford Knee Score - English for Canada measure: Knee Society Score (KSS) measure: Presence of MRSA measure: Microbial Diversity - Taxonomic Differences measure: Microbial Diversity - Taxonomic Correlation measure: Diet and Supplement Questionnaire measure: Histopathology measure: Immunohistochemistry measure: Inflammatory Blood Marker: C-Reactive Protein measure: Inflammatory Blood Marker: Interleukin-1B measure: Inflammatory Blood Marker: Interleukin-6 measure: Inflammatory Blood Marker: Interleukin-8 measure: Inflammatory Blood Marker: Tumor Necrosis Factor Alpha measure: Inflammatory Blood Marker: Erythrocyte Sedimentation Rate measure: Inflammatory Blood Marker: Alkaline Phosphatase measure: Inflammatory Blood Marker: Calcium measure: Inflammatory Blood Marker: Albumin measure: Inflammatory Blood Marker: Urate measure: Inflammatory Blood Marker: Total Protein measure: Inflammatory Blood Marker: Creatinine measure: Inflammatory Blood Marker: Vitamin D measure: Inflammatory Blood Marker: White Blood Cell Count measure: Inflammatory Blood Marker: Red Blood Cell Count measure: Inflammatory Blood Marker: Hemoglobin Concentration measure: Inflammatory Blood Marker: Hematocrit Percentage measure: Inflammatory Blood Marker: Platelet Count sex: FEMALE minimumAge: 55 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: London Health Sciences Centre city: London state: Ontario zip: N6A 5A5 country: Canada name: Rachel Vander Deen role: CONTACT phone: 519-685-8500 phoneExt: 34269 email: Rachel.VanderDeen@lhsc.on.ca name: Lyndsay Somerville, PhD role: CONTACT phone: 519-685-8500 phoneExt: 36645 email: Lyndsay.Somerville@lhsc.on.ca name: Brent Lanting, MD role: PRINCIPAL_INVESTIGATOR name: Jeremy Burton, PhD role: SUB_INVESTIGATOR name: Tom Appleton, PhD role: SUB_INVESTIGATOR name: Matthew Teeter, PhD role: SUB_INVESTIGATOR name: Jonath Thiessen, PhD role: SUB_INVESTIGATOR lat: 42.98339 lon: -81.23304 hasResults: False
nctId: NCT06371937 id: 120687 briefTitle: iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease acronym: INFERENCE overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2033-06-30 date: 2033-06-30 date: 2024-04-17 date: 2024-04-25 name: Lawson Health Research Institute class: OTHER name: Greenstone Biosciences, Inc. briefSummary: The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease. conditions: Cardiovascular Diseases conditions: Arrythmia conditions: Cardiomyopathies conditions: Heart Failure conditions: Cerebrovascular Accident conditions: Congenital Heart Disease conditions: Cardiometabolic Syndrome studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: REDCap Database measure: Induced pluripotent stem cell (iPSC) Biobank measure: Differentiation into Cardiovascular lineages measure: Molecular profiling of participants measure: Bioinformatics analysis sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06371924 id: KCH23-156 briefTitle: Immunometabolism of Machine Perfusion Strategies acronym: iMaps overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-05-31 date: 2026-05-31 date: 2024-04-17 date: 2024-04-17 name: King's College Hospital NHS Trust class: OTHER name: King's College London briefSummary: There are not enough donated livers for everybody who needs one, and as a result, thousands of patients worldwide are waiting for liver transplants, with many dying while waiting for a life-saving organ. One reason for this shortage is that some usable livers from donors who are considered of high risk are being thrown away out of concern that they might not work well after transplantation due to a problem called ischaemia reperfusion injury (IRI).
The discarded organs are mostly those coming from donors who have died due to cardiac arrest (called 'donation after circulatory death' or DCD), with only 27% of them being used in the UK. The quality of these DCD organs could be improved by changing how they are preserved after being removed from the donor. The most commonly used strategy is still to remove the livers and put them in an icebox ('static cold storage' or SCS). The alternative approaches, which are more complex and expensive, but that can also improve the quality of the DCD livers, involve using machines to pump fluids through the livers ('machine perfusion' or MP).
There are three MP methods being used in patients: 1) normothermic regional perfusion (NRP), which involves pumping the donor's blood through the liver after the donor has died but the liver is still in the donor's body; 2) normothermic machine perfusion (NMP), in which the liver is pumped with blood outside of the donor's body; and 3) hypothermic machine perfusion (HOPE), which is also used outside of the donor's body by pumping cold fluid into the liver. HOPE and NRP have been shown to improve how well DCD livers function after transplantation. NMP can also improve the quality of the DCD livers, but its main advantage is that it allows confirming that the donated liver functions well before proceeding with the transplant. Until now, there has not been a proper comparison of these methods, and the doctors do not understand well the mechanisms through which MP improves the quality of the DCD livers.
The iInvestigators plan to conduct a study where 36 DCD human livers will be split into three groups: SCS, NRP, and HOPE. After that, they will be put in NMP to confirm that they are good enough to be transplanted and to study the mechanisms through which NRP, SCS and HOPE work. conditions: Liver Transplantation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The investigators propose to conduct a randomised clinical trial in which 36 DCD human livers will be allocated to 1 of 3 treatment arms:
i) SCS; ii)NRP; and iii) HOPE. This will be followed by a period of time in NMP in order to study the IRI response and determine if the quality of the livers is good enough to proceed to transplantation. This study will allow the doctors to decipher the mechanisms of liver IRI in humans in a much better way than what has been achieved to date. primaryPurpose: OTHER masking: NONE count: 36 type: ESTIMATED name: Machine Perfusion measure: To determine the effect of different preservation strategies on the development of mitochondrial damage following reperfusion during NMP. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06371911 id: 2023-A02762-43 briefTitle: Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment acronym: OPTIMACURE overallStatus: RECRUITING date: 2024-04-03 date: 2024-08-03 date: 2024-12-03 date: 2024-04-17 date: 2024-04-18 name: Centre Francois Baclesse class: OTHER name: Cureety briefSummary: Currently, during usual care, it is critical to assess whether a patient is apt to receive injectable anticancer treatment in the days prior to the administration. To assess this, blood tests are usually performed in the days leading up to the planned administration. A hospital staff member then telephones the patients and evaluates, using the tests results and other patient data (including the presence of adverse events (AEs) and Eastern Cooperative Oncology Group \[ECOG\] performance status), whether the patient is apt for treatment or whether the treatment needs to be deferred.
Since the deployment of the OPTIMA program (between 2014 and 2016), and other equivalent programs, more and more patients have asked for the telephone calls to be replaced by a web-based application. Indeed, patients do not always respond to the telephone calls made by hospital staff, thus forcing staff to repeat calls several times. Also, some patients with language or hearing difficulties are unable to answer the questionnaires by telephone: a web-based alternative would be more appropriate for these patients.
Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool includes questionnaires for each class of medication to monitor patients' adverse events remotely. The data collected include blood results, treatment-related data (including delays, dose reductions), as well as QoL and safety data. In terms of safety, patients respond to an electronic patient-reported outcome (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0. Depending on the responses, the Cureety TechCare algorithm classifies the patient state as "correct", "compromised", "to be monitored", or "critical". The patients are then notified of the actions to be taken according to their classification. In preparation for injectable cancer treatment, Cureety can collect the data necessary to evaluate whether patients are apt for treatment administration. The collection and evaluation of this data is expected to decrease outgoing calls by between 30% to 50%.
This study was designed to evaluate whether adding Cureety telemonitoring to usual care would reduce the number of outgoing calls for hospital staff during the management of patients undergoing injectable at one of the participating centers compared with the usual care including a program for anticipation of injectable treatment (OPTIMA program or equivalent). conditions: Adult Patients Initiating Injectable Anticancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 192 type: ESTIMATED name: Cureety telemonitoring name: OPTIMA or equivalent programs measure: Effectiveness of adding Cureety telemonitoring to usual care sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre hospitalier de Bligny status: NOT_YET_RECRUITING city: Bligny country: France name: Jean-Baptiste MERRIC, MD role: CONTACT email: jb.meric@chbligny.fr name: Jean-Baptiste MERRIC, MD role: PRINCIPAL_INVESTIGATOR facility: Centre François Baclesse status: RECRUITING city: Caen zip: 14000 country: France name: Audrey Faveyrial, MD role: CONTACT email: a.faveyrial@baclesse.unicancer.fr name: Jean-Michel Grellard role: CONTACT email: jm.grellard@baclesse.unicancer.fr name: Audrey Faveyrial, MD role: PRINCIPAL_INVESTIGATOR lat: 49.18585 lon: -0.35912 facility: Centre de Radiothérapie et Oncologie Médicale d'Osny status: NOT_YET_RECRUITING city: Osny country: France name: Abderrezak LADOUANI, MD role: CONTACT email: a.ladouani@crom95.com name: Abderrezak LADOUANI, MD role: PRINCIPAL_INVESTIGATOR lat: 49.0701 lon: 2.06277 hasResults: False
nctId: NCT06371898 id: 29BRC24.0088 - MORDIGO briefTitle: Comparison of MORbidity of Submucosal DIssection Resection of Giant cOlon Lesions Versus Surgery: a National Multicenter Study (MORDIGO) acronym: MORDIGO overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-18 date: 2025-06-17 date: 2025-06-17 date: 2024-04-17 date: 2024-04-17 name: University Hospital, Brest class: OTHER briefSummary: Propose a one-piece endoscopic resection such as endoscopic submucosal dissection (ESD) rather than surgery for benign lesions and superficial T1 cancers colorectal cancers offers comparable efficacy with better tolerability. This approach is all the more in the rectum, even for giant lesions lesions (over 8cm), as rectal surgery is particularly morbid, with particularly morbid, with a functional impact that can impact, whereas rectal ESD is less prone to complications fewer complications than in the colon. Colonic ESD for giant lesions is a longer and more morbid more time-consuming and morbid than for smaller lesions, the question of colonic surgery in this indication. this indication. In order to compare the morbidity data of patients of giant lesions with those of colectomy, a control group colectomy, a surgical control group will be set up, including patients including patients having undergone surgery for in situ T1 or T2 in situ colon cancer. Surgical resections of resection of benign lesions is generally not indicated not indicated and would not provide the necessary necessary for a comparison. T3 and T4 lesions with their own their own morbidity will be excluded. conditions: Colonic Neoplasms studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED measure: 30 days severe morbidity measure: morbidity of ESD group measure: comparison of morbidity in both groups measure: reintervention measure: stomia measure: length of hospital stay measure: readmission measure: mortality measure: risk factors for morbidity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chu Brest city: Brest zip: 29609 country: France lat: 48.3903 lon: -4.48628 hasResults: False
nctId: NCT06371885 id: P.T.REC/012/004646 briefTitle: Shock Wave on Pillar Pain After Carpal Tunnel Release in Hand Burn overallStatus: ACTIVE_NOT_RECRUITING date: 2023-08-10 date: 2024-05-30 date: 2024-06-28 date: 2024-04-17 date: 2024-04-17 name: Cairo University class: OTHER briefSummary: "In burn cases, the reported causes of CTS are increased volume of carpal tunnel content due to edema and synovitis, wrist hyperextension, tight dressing, fibrosis, and direct burn to the nerve. There are two types of pain that occur in the palm of the hand after carpal tunnel surgery: incisional pain and pillar pain. The incision pain typically only lasts for a few days or weeks after surgery, while the pillar pain occurs on the sides of the incision in the thicker parts of the palm, called the thenar and hypothenar eminences. This is where the transverse ligament attaches to the carpal bones, forming the carpal tunnel.
So, in this study we will find out if shock wave therapy has therapeutic effect on pillar pain after carpal tunnel release in hand burn. conditions: Hand Burn conditions: Carpal Tunnel Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Interventional (clinical trial) primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Double mask for both groups (participant) whoMasked: PARTICIPANT count: 52 type: ACTUAL name: shock wave therapy name: traditional physical therapy measure: Visual Analog Scale measure: Hand held dynamometer measure: Michigan hand out Comes questionnaire sex: ALL minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: Shaimaa Mohamed Ahmed El Sayeh city: Cairo state: New Cairo zip: 02 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06371872 id: 2024-A00173-44 briefTitle: French Cohort of Patients With Rotator Cuff Lesions acronym: PRO-CUFF overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2035-12 date: 2035-12 date: 2024-04-17 date: 2024-04-17 name: GCS Ramsay Santé pour l'Enseignement et la Recherche class: OTHER briefSummary: The purpose of this study is to identify, at 5 years, the clinical and therapeutic factors associated with improvement in shoulder functionality and quality of life in patients with transfixing (total) rotator cuff injuries undergoing treatment. conditions: Rotator Cuff Injuries studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 519 type: ESTIMATED name: total transfixing injury to the rotator cuff measure: Shoulder Pain and Disability Index measure: European quality of life scale - EQ5D sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique Maussins-Nollet city: Paris zip: 75019 country: France name: Geoffroy NOURISSAT, MD role: CONTACT email: gnourissat@wanadoo.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06371859 id: 3-3031-2915/1 briefTitle: Human-AI Collaborative Intelligence for Improving Fetal Flow Management overallStatus: RECRUITING date: 2024-04-15 date: 2024-12-01 date: 2025-12-01 date: 2024-04-17 date: 2024-04-23 name: Rigshospitalet, Denmark class: OTHER name: Slagelse Hospital name: Technical University of Denmark briefSummary: This randomized controlled study evaluates the effectiveness of explainable AI (XAI) in improving clinicians' interpretation of Doppler ultrasound images (UA and MCA) in obstetrics. It involves 92 clinicians, randomized into intervention and control groups. The intervention group receives XAI feedback, aiming to enhance accuracy in ultrasound interpretation and medical decision-making.
2. To test the effects of providing Explainable AI (XAI)-feedback for clinicians compared with no feedback on their accuracy in ultrasound interpretation and management. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE maskingDescription: Sealed envelopes will be used and opened at the time of inclusion of each participant. Each participant will be randomized to either AI support or no support. The allocation of participants will be performed by (XYZ) who does not have access to the randomization order. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 92 type: ESTIMATED name: "XAI feedback on MCA/UA Doppler spectral curves and gate placement suggestions" measure: Responses will be reviewed independently by two fetal medicine sonographers, and in case of disagreement between the two experts, a consensus will be reached. measure: Accuracy of flow image management among competence groups sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Rigshospitalet status: RECRUITING city: Copenhagen state: Capital Region Of Denmark zip: 2100 country: Denmark name: Zahra Bashir, MD role: CONTACT name: Zahra Bashir, MD role: PRINCIPAL_INVESTIGATOR lat: 55.67594 lon: 12.56553 facility: Slagelse Hospital status: RECRUITING city: Slagelse state: Region Zealand zip: 4200 country: Denmark name: Zahra Bashir, MD role: CONTACT name: Zahra Bashir, MD role: PRINCIPAL_INVESTIGATOR lat: 55.40276 lon: 11.35459 hasResults: False
nctId: NCT06371846 id: 2023 /10850/I briefTitle: Comparative Study of the Surface Electrocardiogram Signals During the Implantation of Conduction System Pacing Devices overallStatus: RECRUITING date: 2023-03-14 date: 2024-06-30 date: 2024-07-30 date: 2024-04-17 date: 2024-04-17 name: Parc de Salut Mar class: OTHER briefSummary: Introduction and objectives: Left bundle branch area pacing (LBBAP), is a novel modality of physiologic pacing that requires an adequate assessment of the endocardium as well as the body-surface electrocardiographic signals for a successful pacing-lead implantation. The objective of the study consist of assessing if LBBAP criteria, specifically septal and left bundle branch pacing (LBBP) criteria, can be satisfactory measured using the signals resulting from different cardiac pacing analyzers (PSAs) by comparing them to the 'conventional' signals obtained from multichannel polygraph systems (MPSs) during the implantation procedure.
Methods: Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention. conditions: Conduction Disorder conditions: Pacemaker DDD studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 78 type: ESTIMATED name: Selected signals from Pacing System Analyzers measure: Similarity of signals between multichannel recording system and Pacing System Analyzers measure: Security sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jesus Jiménez López status: RECRUITING city: Barcelona state: Cataluña zip: 08005 country: Spain name: Jesus Jiménez López role: CONTACT phone: 680714927 email: jejilo78@gmail.com lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06371833 id: S-52 briefTitle: PRIMA EU Retrospective & Prospective overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2026-12 date: 2024-04-17 date: 2024-04-17 name: Limacorporate S.p.a class: INDUSTRY name: Iqvia Pty Ltd briefSummary: This clinical study aims at evaluating clinical, radiographic and patient-reported outcomes after total anatomic or reverse shoulder replacement using PRIMA humeral stem up to 24 months after surgery, in order to assess the short-term performance of the implant. Furthermore, the objective is also to collect short-term data on the survivorship of the implant and the incidence of complications. conditions: Arthroplasty conditions: Replacement conditions: Shoulder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 60 type: ESTIMATED name: Shoulder Arthroplasy with PRIMA humeral stem measure: Changes of Costant Murley Score (CS) measure: Changes in the American Shoudler and Elbow Surgeons (ASES) score measure: Changes in Range of Motion measures measure: Radiographic stability of the humeral component measure: Survival rate (Kaplan-Meier estimate) measure: Incidence, type and severity of Adverse Events and Adverse Device Effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06371820 id: 2014/1287-31/4 briefTitle: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden) acronym: ESPRESSO overallStatus: ACTIVE_NOT_RECRUITING date: 1965-01-01 date: 2043-05-17 date: 2043-05-17 date: 2024-04-17 date: 2024-04-17 name: Karolinska Institutet class: OTHER briefSummary: The ESPRESSO study is a collection of data from all computerised gastrointestinal histopathology reports in Sweden. This allows us to study risk factors for gastrointestinal disease, as well as the prognosis of gastrointestinal disease.
https://pubmed.ncbi.nlm.nih.gov/30679926/ conditions: Gastrointestinal Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 13000000 type: ACTUAL name: ESPRESSO [The study has no intervention] measure: Incident Mortality [especially rates] measure: Incident Cancer measure: Incident Cardiovascular disease measure: Incident Neurological disease measure: Incident Autoimmune diseases measure: Please note that the recorded outcomes above are examples. Other outcomes may also be studied. sex: ALL minimumAge: 0 Years maximumAge: 110 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False